Texas A&M Football

Lunch with Liucci: Billy Liucci joins TexAgs Radio (Monday, October 9)

TexAgs co-owner and executive editor Billy Liucci joined TexAgs Radio Monday morning to share his thoughts following Texas A&M's loss to No. 11 Alabama at Kyle Field. Liucci talked about what went awry for the Aggies, how the loss will impact the rest of the season and more.
By Billy Liucci
October 9, 2023
4.5k Views
Discuss
Story Poster

TexAgs co-owner and executive editor Billy Liucci joined TexAgs Radio Monday morning to share his thoughts following Texas A&M's loss to No. 11 Alabama at Kyle Field. Liucci talked about what went awry for the Aggies, how the loss will impact the rest of the season and more.


Segment 1 (00:00:00 - 13:12:15)

  • You heard Paul Finebaum say SEC Nation will be in Knoxville this weekend. It's another big game in the SEC. I love Texas A&M moving to this conference.
To view this content, you must be a TexAgs Premium subscriber.
Try Premium for $1
See Subscription Benefits
Trial only available to users who have never subscribed or participated in a previous trial
Discuss
Tags
Jackie Sherrill TexAgs Live R.C. Slocum 12th Man Foundation TexAgs Live Feature Lunch with Liucci Mario Cristobal Spencer Rattler Will Rogers Jermaine Burton Bru McCoy Tyler Van Dyke
Show All
Jalin Hyatt Texas A&M vs. Alabama Texas A&M at Tennessee Max Wright Micheal Clemons Ainias Smith Devon Achane Max Johnson Jake Johnson Edgerrin Cooper Le'Veon Moss Evan Stewart Football Texas A&M LSU Tennessee Georgia Tech Miami Alabama Ole Miss 2023
SPONSORED BY
12th Man Foundation
More Football
See All →
Texas A&M holds steady at No. 3 in AP poll following second bye week
By Richard Zane
This Week on Take Five: Concepcion, Boerkircher, Freshcorn, Fitch & Perez
By Richard Zane
Pick Six: The TexAgs crew picks six games against the spread
By TexAgs Live
Howell both talks the talk and walks the walk on his reign of terror
By Olin Buchanan
 
×
subscribe Verify your student status
See Subscription Benefits
Trial only available to users who have never subscribed or participated in a previous trial.